1.Study Shows Strong Tobacco Control Programs and Policies Can Lower Smoking Rates (Posted: 11/18/2003, Updated: 06/16/2004) - A study published today in the Journal of the National Cancer Institute provides the latest evidence that investing in state tobacco control programs can reduce smoking rates. 2.Post-Surgery Chemotherapy Improves Survival in Early Lung Cancer (Posted: 06/05/2004) - Two large randomized studies show that in early-stage non-small cell lung cancer, treatment after surgery with chemotherapy improves overall survival compared to surgery alone. The findings help resolve a controversy over the value of post-surgical chemotherapy for early lung cancer and are likely to change the standard of care. 3.Erlotinib (Tarceva®) Extends Survival in Advanced Lung Cancer (Posted: 06/05/2004) - Erlotinib (Tarceva®) prolonged survival in patients with advanced non-small cell lung cancer who had progressed after standard chemotherapy, according to findings reported at the 2004 ASCO meeting in New Orleans. 4.Pemetrexed (Alimta®) Is a Less-Toxic Alternative for Recurrent Lung Cancer (Posted: 06/12/2003, Updated: 05/05/2004) - The experimental drug pemetrexed (Alimta®) was as effective as the current standard treatment for recurrent non-small cell lung cancer (NSCLC) and caused fewer side effects, according to data presented at American Society of Clinical Oncology (ASCO) annual meeting on June 2, 2003. 5.Presence of Gene Mutation Tightly Linked to Drug Effectiveness in Lung Cancer (Posted: 04/29/2004) - Mutation of a gene involved in non-small cell lung cancer (NSCLC) increases the likelihood that the drug gefitinib (Iressa) will show a beneficial response.
